Brixadi FDA Approval Status
FDA Approved: No
Brand name: Brixadi
Generic name: buprenorphine
Dosage form: Extended-Release Injection
Company: Braeburn Inc.
Treatment for: Opiate Dependence
Brixadi (buprenorphine) is a long-acting partial opioid agonist injection formulation in development for the treatment of opioid use disorder.
Development Timeline for Brixadi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.